Abstract: Open-loop postprandial glucose control can be posed as a set-inversion problem. Given a set of constraints on postprandial glucose, an insulin infusion profile is sought so that the constraints are fulfilled. In this work, a general framework for the consideration of intra-patient variability in set-inversion-based postprandial glucose control is presented. Patient's model parameters are considered to vary in an interval describing the variability observed for that patient. Different possibility degrees can be associated to the intervals of variation, generalizing to a fuzzy approach ranging from a best-case to a worst-case scenario of variability. Different degrees of relaxation are considered for the specifications. Hard specifications are demanded for the best-case scenario, whereas soft (limit) specifications are defined for the worst-case. The methodology is demonstrated through a practical application.
INTRODUCTION
Type 1 diabetes mellitus (T1DM) is a disease characterized by the impossibility of a patient's pancreas to produce insulin. This determines excessive hepatic glucose production and impedes uptake of glucose by muscle and adipose tissue, producing high blood glucose concentrations that lead to severe long-term complications to the patient. The absence of endogenous insulin production can be substituted with administration of exogenous insulin, either by periodic insulin injections that the patient has to deliver to himself, or continuous infusion through insulin pumps. However, despite medical and scientific progresses, insulin replacement is still an empirical process, and maintaining plasma glucose in physiological range is extremely difficult.
Challenges for tight glycemic control are many. Patient's sensitivity to insulin is time-varying, affected by circadian rhythms, which leads to different insulin requirements depending on the time of the day (Waldhäusl, 1989) . It is also affected by strong disturbances such as exercise, stress or disease state (Bevier et al., 2008; McMahon et al., 2007) . This leads to a great intra-individual variability This research is partially supported by the Spanish Ministry of Science and Innovation through the grants DPI2007-66728-C02, DPI2010-20764-C02 and FEDER funds from the European Union that has to be addressed appropriately. This variability is also present in other physiological processes involved in the glucoregulatory path, such as subcutaneous insulin absorption (Heinemann, 2002; Gin and Hanaire-Broutin, 2005; Hompesch et al., 2008) or meal digestion and absorption (Dalla Man et al., 2006) . Indeed, postprandial glucose control (after meals) is one of the biggest challenges found not only in current open-loop strategies, but also in closedloop control as demonstrated by clinical results of artificial pancreas prototypes (Bruttomesso et al., 2009; Clarke et al., 2009; Hovorka et al., 2010) .
Interval methods (Moore, 1966) have been successfully applied in a great variety of engineering applications to yield robust control strategies for uncertain plants. Indeed, intervals are a natural way to express uncertainty in model parameters, inputs and initial conditions. These methods were first introduced in (Bondia et al., 2009; Revert et al., 2011 Revert et al., , 2010 in the context of postprandial glucose control to compute the feasible set of insulin infusion profiles to fulfill the International Diabetes Federation (IDF) recommendations on postprandial glycemia (International Diabetes Federation, 2007) , according to a patient's mathematical prediction model. A set of infusion profiles can be represented as an uncertain input in the patient's model and its feasibility checked by means of interval simulation and branch-and-bound techniques (setinversion algorithm). However, in these previous works, patient's model parameters were considered time-invariant.
In this work, the method is extended to deal with intrapatient variability. Patient's model parameters are considered to vary in an interval describing the variability observed for that patient. Different possibility degrees can be associated to the intervals of variation, generalizing to a fuzzy approach ranging from a best-case to a worst-case scenario of variability. Different degrees of relaxation are considered for the specifications. Hard specifications are demanded for the best-case scenario, whereas soft (limit) specifications are defined for the worst-case, controlling performance degradation.
Section 2 describes the basic set inversion algorithm for postprandial glucose control. Next, a general framework to represent patient's variability is presented, as well as inclusion of hard/soft constraints into the methodology. Finally, application of the algorithm is demonstrated and conclusions are drawn.
In the following,x denotes a real interval, and x − , x + are its left and right endpoints. Interval vectors, or boxes, are denoted in boldface,x. The set of all real intervals is denoted by IR and the set of n-dimensional boxes as IR n . Similarly, the notationx,x is used to denote fuzzy numbers and vectors, respectively.
SET-INVERSION-BASED POSTPRANDIAL GLUCOSE CONTROL
Open-loop postprandial glucose control can be naturally posed as a set-inversion problem. Given a set of constraints on postprandial glucose, an insulin infusion profile is sought so that the constraints are fulfilled. Set inversion characterizes the set of all feasible infusion profiles (according to some input parameterization), from which a selection based on some optimality or clinical criteria can be performed.
Formally, the set inversion problem is defined as follows. Definition 2.1. (Set inversion problem). Let X ⊆ R n and Y ⊆ R m be an input and output space, respectively. Given a set Y ⊆ Y and a map f : X → Y, find the set
The set Y is usually defined through constraints on the output space. The Set Inversion Via Interval Analysis (SIVIA) algorithm (Jaulin et al., 2001 ) makes use of a branch-and-bound technique together with interval analysis (Moore, 1966) to get an approximation of the solution set X . This approximation is done in terms of subpavings (collection of boxes of the appropriate dimension with non-overlapping interiors). An inner and outer subpaving, here denoted as [X ] Figure 1 ).
In the case under consideration, the following set inversion problem is posed: Fig. 1 . Inner subpaving (blue boxes) and outer subpaving (blue + red boxes) in the case of a therapy described by the bolus insulin dose and basal insulin rate at mealtime.
• The input space X corresponds to a parameterization of the insulin infusion profile.
• The output space Y corresponds to the set of postprandial glucose excursions up to a given timehorizon.
• The set Y is defined as a set of constraints on the postprandial glucose excursions, denoted here as C(g(t)).
• The map f corresponds to the patient's model, mapping an insulin profile with a postprandial glucose excursion.
The SIVIA algorithm works as follows. For a given box x in the input space (set of insulin infusion profiles) and the set of constraints C(g(t)), a test function determines whether: (1) all the insulin therapies contained inx fulfill the constraints (True box); (2) none of the insulin therapies contained inx fulfill the constraints (False box); (3) some of the therapies inx fulfill the constraints, while others do not (Indeterminate box). The collection of input boxes classified as True constitute the inner subpaving. Boxes classified as indeterminate are halved, repeating the procedure for each sub-box until a minimum width is reached. The True boxes plus the Indeterminate -boxes constitute the outer subpaving.
Test function is built from an interval simulator of a patient's model. An interval simulator allows to simulate a model in face of uncertainty in the inputs, initial state and model parameters, in a computationally efficient way . In the case under consideration, the interval simulator yields an upper and lower envelope of all the possible postprandial glucose excursions for the given input boxx (i.e. set of insulin infusion profiles) (see Figure  2 for an illustration). Intra-patient variability may also be considered as interval model parameters (see Section 3). Thus, for a given time t, an intervalḡ(t) of glucose values is obtained. Comparison against the constraints C(g(t)) allows to classify the input box as:
• True: ∀t ∈ [0, t max ], ∀g ∈ḡ(t), C(g) = true.
• False: ∃t ∈ [0, t max ], ∀g ∈ḡ(t), C(g) = false.
• Indeterminate: otherwise.
Regarding the patient's model, current comprehensive and widely accepted models such as Wilinska et al. (2010) and Dalla ity problems in ambulatory conditions. Simpler models must be used for the practical implementation of modelbased control strategies, since no tracer data will be available for their identification during clinical practice. The model used here is a combination of Wilinska's model for subcutaneous insulin absorption (Wilinska et al., 2005) , Dalla Man's model for glucose absorption from the gut (Dalla Man et al., 2006 ) and a modified version of Panunzi's model (Panunzi et al., 2007) for the endogenous glucoregulation (Laguna et al., 2010) . This combination was chosen to get a good balance between model identifiability and model complexity. However, remark that the method can be used with any patient's model as long as an interval simulator is built for it ).
Wilinska's model is a parallel inputs pharmacokinetic model consisting in fast and slow absorption channels with local insulin degradation. It showed good fitting properties in (Wilinska et al., 2005) , where a thorough comparison between insulin pharmacokinetic models was carried out. Dalla Man's model is a non-linear model consisting in two compartments representing different stages in the digestion of carbohydrates in the stomach and a compartment representing the gut. Gastric emptying is a non-linear function of the total amount of glucose in the stomach mimicking the influence of fat (delaying absorption). The model was validated in a triple tracer experiment with a "mixed meal" (Basu et al., 2003) , and it corresponds to the model included in Dalla Man et al. (2007) . As it is assumed here that dynamics is dominantly determined by meal absorption during postprandial state, a simple model is used to describe endogenous glucoregulation, contrary to meal absorption. The model published by Panunzi et al. (2007) , describing the Intravenous Glucose Tolerance Test (IVGTT) in healthy people, was adapted here, with the elimination of the insulin secretion and the inclusion of a delay in insulin action (Laguna et al., 2010) . The model is defined by the equations:
with
where G(t) is blood glucose concentration, i(t) plasma insulin, G ex (t) glucose rate of appearance from the gut, X(t) delayed insulin action with a time constant 1/k i , K xgl patient's insulin sensitivity and T gh (t) balance between hepatic production and non-insulin-dependent uptake. Nominal rate T 0 gh is reduced in a factor α < 1 when plasma insulin is above a given threshold i 0 . V g is the glucose distribution volume per unit of body weight (BW ).
INCORPORATING INTRA-PATIENT VARIABILITY: INTERVAL AND FUZZY MODELS
Intra-patient variability can be naturally incorporated in the above methodology if time-varying uncertain parameters are used in the interval simulator, without any extra computational cost. In this case, the patient's model is described by an interval model
y = h(x, u;p) with x, u, y the state, input and output vector, and p ∈ IR np a vector of interval parameters describing patient's variability, such as insulin sensitivity, glucose gut absorption rate, subcutaneous insulin absorption rate, etc, so that p(t) ∈p, ∀t ∈ [0, ∞). Remark that parameters are considered to vary between the bounds of the (functional) interval, and not fixed but uncertain values, since this latter case would not reflect a realistic situation (Figure 3,  left) . Furthermore, this is in accordance with the output produced by interval simulators, based on discretizations of the model, which consider interval parameters at different time instants independent.
Interval bounds can be also considered time-varying, so that p(t) ∈p(t) : Figure  3 , right). This is useful, for instance, to represent uncertain circadian variations of parameters such as insulin sensitivity, where the interval bounds follow a given periodic pattern.
In a more general framework, intervals of variation can be assigned a possibility degree α ∈ [0, 1], grading from a best-case scenario to a worst-case one. This leads to fuzzyparametric models of the forṁ corresponds to the worst case interval of variation. The set with unity possibility {p i ∈ R |µp i (p i ) = 1} (kernel of the fuzzy number/interval) represents the best scenario considered. Again, for a given possibility degree, parameters are considered to vary in the corresponding α-cut.
Similarly to the interval case, α-cut bounds can be timevarying (see Figure 5 ).
Fuzzy-parametric models are useful to account for variations of patient's variability due to different patient states or to distinguish between a nominal (average) patient behavior vs. a worst case scenario of variability (see Section 5 for an illustration). In the case only two degrees of possibility are considered (0 and 1), fuzzy sets reduce to rough sets (Pawlak, 1982) . This is the approach considered here (Section 5).
From the computational point of view, simulation of fuzzyparametric models is carried out through a discretization of the possibility degree α (nested set of intervals), reducing to multiple interval simulations.
HARD/SOFT SPECIFICATIONS
Given the fuzzy-parametric model (5) describing patient's variability, a specifications set can be associated to each α-cut ( Figure 6 ). Thus, specifications for the kernel represent the glycemic control performance demanded to the bestcase scenario of variability ("hard" specification), whereas specifications for the support represent the worst-case performance that may be accepted ("soft" specification) (Bondia et al., 2005) . Different gradings controlling performance degradation can be defined for intermediate α-cuts, although this will not be necessary in many practical applications reducing to the rough set case. Specifications for a given α-cut are represented by a set of constraints on postprandial glucose excursions C α (g(t)).
Thus, denoting [X ]
α i the inner subpaving of the solution set for the cut α, and C α (g(t)) the constraints on postprandial glucose demanded for that degree of variability, an inner subpaving of the global solution set is given by:
so that any elementx ∈ [X ] i fulfills simultaneously all the constraints on glucose C α (g(t)).
From a computational point of view, it is not necessary to compute all the inner subpavings [X ]
α i . The problem can be equivalently posed considering the set of constraints
in the test function of the set inversion algorithm in Section 2, where ∧ denotes the logical AND operator. In this case, an input boxx is classified according to the following criteria:
• Indeterminate: otherwise, whereḡ α (t) denotes the glucose interval at time t obtained by the interval simulator of the patient's model considering the level of variability given by the cut α, and g α denotes a real value in the intervalḡ α (t).
In case constraints C α (g(t)) are incompatible, the intersection (6) will be the empty set. In this case constraints need to be necessarily relaxed.
RESULTS
In the above sections, a general framework for setinversion-based postprandial glucose control with consideration of patient's variability has been presented. Here, application of the algorithm is demonstrated.
Building the uncertain patient's model
A key element in the methodology is building a patient's model characterizing the postprandial period. In Laguna et al. (2010) an optimal experiment design was carried out to maximize parameter identifiability of the model described in Section 2 based on ambulatory data from a continuous glucose monitor, insulin pump and patient's logbook. There it is proved that separation of insulin bolus and meal intake, contrary to the standard treatment, is required to avoid unidentifiability issues, combining small and big meals. Based on these results, patients at Valencia Clinic University Hospital were instructed to follow the following clinical protocol during three days at lunchtime for model identification:
• If the patient has a blood glucose level over 150 mg/dl or in the 100-150 mg/dl range with an increasing trend (hyperglycaemic risk), the insulin bolus is given followed 30 minutes later by a 100 grams meal.
• If the glucose level is below 100 mg/dl or in the 100-150 mg/dl range with a decreasing trend (hypoglycaemic risk), a 40 grams meal is given and the insulin dose administration is delayed 120 minutes.
In both situations the dose to be administered is the one recommended to the patient, depending on the size of the meal and his/her usual insulin-to-carbohydrate ratio. Patients can choose among three menus with the same relative nutritional composition and are invited to maintain their usual lifestyle. Additionally, data are registered during three more days for the purpose of model validation, where the patient follows the standard treatment. This study is currently ongoing with a target of 12 patients. Figure 7 shows the model fitting for the three identification days in a sample patient. It must be considered here that the same model is being considered during the three days (time-invariant parameters). However, different meals were ingested (although with similar glycemic index and relative nutritional composition) and variability in glucose rate of appearance from the meal is expected, as well as in patient's insulin sensitivity, among other things. This means that the model identified should be considered kind of "average" model where parameters explain simultaneously the response observed during the three days.
Model validation against the three validation days is shown in Figure 8 . The second validation day must be discarded due to malfunction of the continuous glucose monitor. As it is expected, discrepancies exist due (among other things) to patient's variability. Interval simulation allows to quantify the variability exhibited by the patient. An optimal interval simulator was built allowing the computation of the exact glucose envelopes in face of uncertainty in a computationally efficient manner . Figure  9 shows the predictions given by the model considering a 20% uncertainty in insulin sensitivity and 10% uncertainty in the grams of carbohydrates ingested to account for under/overestimations by the patient. Consideration of interval parameters succeeds explaining the response in the first validation day, while estimating acceptably the glycemic range also the third day.
In this case, a rough set approach is considered for the uncertain model definition. The "average" model obtained during the identification days, where the protocol to maximize identifiability was followed, is considered as the bestcase scenario (α = 1), whereas the model with consideration of 20% uncertainty in insulin sensitivity and 10% uncertainty in the grams of carbohydrates is considered as a worst-case scenario (α = 0).
So far, data from 12 weeks of monitoring are available from 5 different patients, showing a fitting mean R 2 of 0.628 (standard deviation 0.268) for a 5-hour prediction. The glycemic exposure of 47% of the validation days was predicted successfully (considering a 20% uncertainty in insulin sensitivity and 10% uncertainty in the grams of carbohydrates), with a mean error of 12.637% (standard deviation 5.932%) for the rest of days. Model refinements may be needed to improve prediction capabilities. However, it is still an open issue how to deal with continuous glucose monitoring errors during identification and validation in the absence of gold standard measurements.
Defining constraints
Hard specifications are defined for the best-case aiming at ideal glycemic control for the "average" behavior, while soft specifications define the worst-case acceptable performance. These specifications are defined in terms of constraints on glucose as follows:
• Hard constraints:
≤ 10 mg/dL/h at 5 hours. 90, 180] mg/dL at 5 hours,
≤ 10 mg/dL/h at 5 hours.
Constraints are built based on the IDF guidelines of nonhypoglycemia (considered here as 70 mg/dL) and 2-h glucose below 140 mg/dL, and terminal constraints to get a stabilizing glucose above 90 mg/dL.
Solution set
A parameterization of the insulin infusion profile consisting on bolus insulin dose, basal insulin dose at mealtime (prandial basal) and time of restoration of basal to its baseline value is considered here (see Figure 10 ). Remark that prandial basal may be above baseline, representing a dual-wave infusion, or below baseline, representing a temporal basal decrement. Thus, a 3D set-inversion problem is posed. Projections of the resulting inner subpaving (6) on the different subspaces are shown in Figure 11 , for 100 grams of carbohydrate intake. Any solution inside the inner subpaving will fulfill both hard and soft specifications. Figure  12 shows the response for a solution of maximum bolus as illustration of an aggressive feasible therapy, corresponding to a bolus dose of 20 U and a prandial basal of 0.1 U/h during 160 min. Baseline basal rate for this patient is 0.55 U/h. Both hard and soft constraints are fulfilled, although the patient may be close to hypoglycemia in the worst case, as expected, due to the aggressiveness of the therapy selected. Any solution chosen close to the boundary of the solution set will yield glucose excursions close to either the hyperglycemia constraint or the hypoglycemia constraint. From the robustness point of view, a centered solution may be chosen. However, it is still unclear the clinical impact of selecting different solutions in the set.
CONCLUSIONS
A general framework to deal with intra-patient variability based on the use of interval / fuzzy-parametric models has been presented and integrated into a set-inversion-based algorithm for postprandial glucose control. The framework allows to tackle with a wide range of applications where a best-case vs. a worst-case of variability can be defined, demanding different levels of performance. Application of the method has been demonstrated to deal with the timeinvariant approach in model parameters identification for patient's exhibiting significant variability.
